Interestingly, data is available on the clinical utility of TROP2 in metastatic HR+/HER2− BC who received anti-TROP2 therapy.14 Accordingly, in this study we aim to assess the significance of TROP2 expression at the protein and transcript levels in early HR+/HER2− BC and explore its relationship with clinico-pathological parameters pre- and post-NAC and survival. Here, TACSTD2 is linked to breast cancer.